The UK's first weight-loss pill is here — and the price war has already started

The UK approved the world's first GLP-1 weight-loss pill — and prices are already diverging

On 11 June 2026, the MHRA gave the green light to oral semaglutide for weight management — the same active ingredient as Wegovy, now in tablet form. The UK is the first country in the world to approve an oral GLP-1 specifically for obesity, and providers moved quickly. Within two weeks, the pill was available from pharmacies, online clinics, and even supermarkets.

The clinical trial data: adults at the 25mg dose lost an average of 13.6% of body weight over 64 weeks — meaningful, but less than the injectable Wegovy (which averages around 15%). The NHS won't fund it until NICE completes its review, a process that typically takes 12–18 months.

Mounjaro is quietly expanding on the NHS — but it depends on your GP

From April 2026, Mounjaro (tirzepatide) was added to the GP Quality and Outcomes Framework, meaning GPs can now prescribe it directly for obesity rather than referring patients to specialist weight services. This is the most significant expansion of NHS access to GLP-1s since Wegovy was first listed.

The eligibility criteria are also broadening. From around now, the threshold is expected to drop to BMI 35+ with four qualifying conditions — down from the stricter criteria that applied earlier in the year. In Scotland, the Scottish Medicines Consortium approved Wegovy this month for patients with obesity and pre-existing cardiovascular disease.

A second oral GLP-1 is already heading to the UK — and it's different

Oral semaglutide is the first pill, but almost certainly not the last. Eli Lilly's orforglipron (brand name: Foundayo) gained FDA approval in the US on 1 April 2026 and is now under MHRA review. A UK launch is expected in late 2026 or early 2027, with private prescriptions likely available first.

The key difference from the Wegovy pill: orforglipron is a small-molecule drug, which means it's stable at room temperature and has no fasting requirements — you can take it with or without food, any time of day. The current oral semaglutide tablet requires a 30-minute fasting window. Clinical trials showed 11–12.4% average weight loss over 72 weeks.

Eli Lilly already makes Mounjaro — the injectable that has taken significant market share from Wegovy in the UK. A second Lilly oral drug entering the market means two major companies competing head-to-head in pill form, which should push prices down over time.

People on GLP-1s are moving less — here's what the research says

Research presented at ENDO 2026 — the world's largest endocrinology conference — found that people taking GLP-1 drugs became significantly less physically active as they lost weight. Average daily steps fell from 5,047 to 4,487, and time in moderate-to-vigorous activity dropped from 28 to 22 minutes per day.

The researchers weren't concluding GLP-1s are harmful — the weight loss benefits are well-established. The finding is more nuanced: the appetite-suppressing effect of the drugs may reduce overall energy levels, and without deliberate effort to maintain activity, some of the metabolic benefits can be partially offset.